OncoSec Medical Incorporated (ONCS) financial statements (2021 and earlier)

Company profile

Business Address 24 N. MAIN STREET
PENNINGTON, NJ 08534
State of Incorp. NV
Fiscal Year End July 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments60202541129
Cash and cash equivalents60202541129
Prepaid expense   211
Other current assets     0
Other undisclosed current assets22323  
Total current assets:632329291329
Noncurrent Assets
Operating lease, right-of-use asset66 
Property, plant and equipment111123
Intangible assets, net (including goodwill)0     
Intangible assets, net (excluding goodwill)0     
Other noncurrent assets000000
Total noncurrent assets:771233
TOTAL ASSETS:703030301532
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:984531
Accrued liabilities001121
Employee-related liabilities00  00
Other undisclosed accounts payable and accrued liabilities87442 
Debt110   
Other undisclosed current liabilities111103
Total current liabilities:11105633
Noncurrent Liabilities
Long-term debt and lease obligation66    
Long-term debt, excluding current maturities00    
Operating lease, liability66 
Liabilities, other than long-term debt  1111
Other liabilities  1111
Other undisclosed noncurrent liabilities(1)(6)    
Total noncurrent liabilities:1161111
Total liabilities:22166754
Stockholders' equity
Stockholders' equity attributable to parent481424231128
Common stock000000
Additional paid in capital2752151781469488
Accumulated other comprehensive income (loss)(0)(0)0(0)(0) 
Accumulated deficit(231)(207)(164)(134)(95)(73)
Warrants and rights outstanding4611111213
Total stockholders' equity:481424231128
TOTAL LIABILITIES AND EQUITY:703030301532

Income statement (P&L) ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
Operating expenses(44)(43)(30)(36)(21)(27)
Operating loss:(44)(43)(30)(36)(21)(27)
Nonoperating income0000  
Foreign currency transaction gain (loss), before tax00(0)   
Interest and debt expense(0)(0)(0)   
Loss from continuing operations before equity method investments, income taxes:(44)(43)(30)(36)(21)(27)
Other undisclosed income (loss) from continuing operations before income taxes00(0)(3)  
Loss from continuing operations before income taxes:(44)(43)(30)(39)(21)(27)
Income tax expense (benefit)11(0)(0)(0)(0)
Net loss attributable to parent:(43)(42)(30)(39)(21)(27)
Other undisclosed net loss available to common stockholders, basic   (95)  
Net loss available to common stockholders, diluted:(43)(42)(30)(134)(21)(27)

Comprehensive Income ($ in millions)

1/31/2021
TTM
7/31/2020
7/31/2019
7/31/2018
7/31/2017
7/31/2016
Net loss:(43)(42)(30)(39)(21)(27)
Other comprehensive income (loss)(1)(0)03921 
Comprehensive income (loss):(43)(42)(30)00(27)
Other undisclosed comprehensive loss, net of tax, attributable to parent   (39)  
Comprehensive income (loss), net of tax, attributable to parent:(43)(42)(30)(39)0(27)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: